192 related articles for article (PubMed ID: 38365636)
21. FOXO4 expression associates with glioblastoma development and FOXO4 expression inhibits cell malignant phenotypes in vitro and in vivo.
Qi M; Sun LA; Jiang XC; Han YL; Wang L; Niu WH; Fei MX; Zhaba WD; Zheng LR; Zhou ML
Life Sci; 2020 Apr; 247():117436. PubMed ID: 32070707
[TBL] [Abstract][Full Text] [Related]
22. Repression of Septin9 and Septin2 suppresses tumor growth of human glioblastoma cells.
Xu D; Liu A; Wang X; Chen Y; Shen Y; Tan Z; Qiu M
Cell Death Dis; 2018 May; 9(5):514. PubMed ID: 29724999
[TBL] [Abstract][Full Text] [Related]
23. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
24. BRD4 inhibitor GNE987 exerts anti-cancer effects by targeting super-enhancers in neuroblastoma.
Chen YL; Li XL; Li G; Tao YF; Zhuo R; Cao HB; Jiao WY; Li ZH; Zhu ZH; Fang F; Xie Y; Liao XM; Wu D; Wang HR; Yu JJ; Jia SQ; Yang Y; Feng CX; Yang PC; Fei XD; Wang JW; Xu YY; Qian GH; Zhang ZM; Pan J
Cell Biosci; 2022 Mar; 12(1):33. PubMed ID: 35303940
[TBL] [Abstract][Full Text] [Related]
25. Over-expressed lncRNA HOTAIRM1 promotes tumor growth and invasion through up-regulating HOXA1 and sequestering G9a/EZH2/Dnmts away from the HOXA1 gene in glioblastoma multiforme.
Li Q; Dong C; Cui J; Wang Y; Hong X
J Exp Clin Cancer Res; 2018 Oct; 37(1):265. PubMed ID: 30376874
[TBL] [Abstract][Full Text] [Related]
26. Echinacoside (ECH) suppresses proliferation, migration, and invasion of human glioblastoma cells by inhibiting Skp2-triggered epithelial-mesenchymal transition (EMT).
Shi S; Qin Y; Chen D; Deng Y; Yin J; Liu S; Yu H; Huang H; Chen C; Wu Y; Zou D; Wang Z
Eur J Pharmacol; 2022 Oct; 932():175176. PubMed ID: 35995211
[TBL] [Abstract][Full Text] [Related]
27. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
28. BRD4 regulates key transcription factors that drive epithelial-mesenchymal transition in castration-resistant prostate cancer.
Shafran JS; Jafari N; Casey AN; Győrffy B; Denis GV
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):268-277. PubMed ID: 32690869
[TBL] [Abstract][Full Text] [Related]
29. Saponin 1 induces apoptosis and suppresses NF-κB-mediated survival signaling in glioblastoma multiforme (GBM).
Li J; Tang H; Zhang Y; Tang C; Li B; Wang Y; Gao Z; Luo P; Yin A; Wang X; Cheng G; Fei Z
PLoS One; 2013; 8(11):e81258. PubMed ID: 24278406
[TBL] [Abstract][Full Text] [Related]
30. Integrative analysis of cell adhesion molecules in glioblastoma identified prostaglandin F2 receptor inhibitor (PTGFRN) as an essential gene.
Mala U; Baral TK; Somasundaram K
BMC Cancer; 2022 Jun; 22(1):642. PubMed ID: 35690717
[TBL] [Abstract][Full Text] [Related]
31. Mir-370-3p Impairs Glioblastoma Stem-Like Cell Malignancy Regulating a Complex Interplay between HMGA2/HIF1A and the Oncogenic Long Non-Coding RNA (lncRNA) NEAT1.
Lulli V; Buccarelli M; Ilari R; Castellani G; De Dominicis C; Di Giamberardino A; D Alessandris QG; Giannetti S; Martini M; Stumpo V; Boe A; De Luca G; Biffoni M; Marziali G; Pallini R; Ricci-Vitiani L
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32443824
[TBL] [Abstract][Full Text] [Related]
32. The transcript ENST00000444125 of lncRNA LINC01503 promotes cancer stem cell properties of glioblastoma cells via reducing FBXW1 mediated GLI2 degradation.
Wei P; Jiang J; Xiao M; Zeng M; Liu X; Zhao B; Chen F
Exp Cell Res; 2022 Mar; 412(1):113009. PubMed ID: 34990616
[TBL] [Abstract][Full Text] [Related]
33. Foretinib induces G2/M cell cycle arrest, apoptosis, and invasion in human glioblastoma cells through c-MET inhibition.
Gortany NK; Panahi G; Ghafari H; Shekari M; Ghazi-Khansari M
Cancer Chemother Pharmacol; 2021 Jun; 87(6):827-842. PubMed ID: 33688998
[TBL] [Abstract][Full Text] [Related]
34. Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor.
Costa B; Bendinelli S; Gabelloni P; Da Pozzo E; Daniele S; Scatena F; Vanacore R; Campiglia P; Bertamino A; Gomez-Monterrey I; Sorriento D; Del Giudice C; Iaccarino G; Novellino E; Martini C
PLoS One; 2013; 8(8):e72281. PubMed ID: 23977270
[TBL] [Abstract][Full Text] [Related]
35. Dissecting the role of novel EZH2 inhibitors in primary glioblastoma cell cultures: effects on proliferation, epithelial-mesenchymal transition, migration, and on the pro-inflammatory phenotype.
Stazi G; Taglieri L; Nicolai A; Romanelli A; Fioravanti R; Morrone S; Sabatino M; Ragno R; Taurone S; Nebbioso M; Carletti R; Artico M; Valente S; Scarpa S; Mai A
Clin Epigenetics; 2019 Dec; 11(1):173. PubMed ID: 31791385
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT.
Zhao C; Guo R; Guan F; Ma S; Li M; Wu J; Liu X; Li H; Yang B
Sci Rep; 2020 Jun; 10(1):9471. PubMed ID: 32528036
[TBL] [Abstract][Full Text] [Related]
37. miR-766-5p Targets Super-Enhancers by Downregulating CBP and BRD4.
Gen Y; Muramatsu T; Inoue J; Inazawa J
Cancer Res; 2021 Oct; 81(20):5190-5201. PubMed ID: 34353856
[TBL] [Abstract][Full Text] [Related]
38. The lncRNA RP3-439F8.1 promotes GBM cell proliferation and progression by sponging miR-139-5p to upregulate NR5A2.
Qi J; Pan L; Yu Z; Ni W
Pathol Res Pract; 2021 Jul; 223():153319. PubMed ID: 33991848
[TBL] [Abstract][Full Text] [Related]
39. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
40. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer.
Noblejas-López MDM; Nieto-Jimenez C; Burgos M; Gómez-Juárez M; Montero JC; Esparís-Ogando A; Pandiella A; Galán-Moya EM; Ocaña A
J Exp Clin Cancer Res; 2019 Aug; 38(1):383. PubMed ID: 31470872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
